A5052864271- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Advanced Breast Cancer Therapies
- DNA Repair Mechanisms
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Advanced Proteomics Techniques and Applications
- Breast Lesions and Carcinomas
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Molecular Biology Techniques and Applications
- Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Radiomics and Machine Learning in Medical Imaging
- Breast Implant and Reconstruction
- Colorectal Cancer Treatments and Studies
- Epigenetics and DNA Methylation
- Cell Adhesion Molecules Research
- Monoclonal and Polyclonal Antibodies Research
Jewish General Hospital
2016-2025
McGill University
2016-2025
Weatherford College
2024
McGill University Health Centre
2010-2023
Health Net
2023
University Health Network
2023
NRG Oncology
2019-2021
Royal Victoria Hospital
2020
Allegheny Health Network
2019
Orlando Health
2019
The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity in multiple epithelial tumor types; however, responses are seen only a subset of patients. This study was conducted to identify markers that associated with disease control patients treated cetuximab.One hundred ten metastatic colorectal cancer were enrolled onto monotherapy trial. Transcriptional profiling on RNA from mandatory pretreatment biopsies genes whose expression correlates best clinical responses....
Purpose An increasing proportion of patients (> 30%) with node-positive breast cancer will obtain an axillary pathologic complete response after neoadjuvant chemotherapy (NAC). If sentinel node (SN) biopsy (SNB) is accurate in this setting, completion dissection (CND) morbidity could be avoided. Patients and Methods In the prospective multicentric SN FNAC study, biopsy-proven (T0-3, N1-2) underwent both SNB CND. Immunohistochemistry (IHC) use was mandatory, metastases any size, including...
Abstract The administration of ex vivo culture-expanded mesenchymal stromal cells (MSCs) has been shown to reverse symptomatic neuroinflammation observed in experimental autoimmune encephalomyelitis (EAE). mechanism by which this therapeutic effect occurs remains unknown. In an effort decipher MSC mode action, we found that conditioned medium inhibits EAE-derived CD4 T cell activation suppressing STAT3 phosphorylation via MSC-derived CCL2. Further analysis demonstrates the is dependent on...
Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results.
Cancer cell genomes contain alterations beyond known etiologic events, but their total number has been unknown at even the order of magnitude level. By sampling colorectal premalignant polyp and carcinoma through use technique inter-(simple sequence repeat) PCR, we have found genomic to be considerably more abundant than expected, with mean events per totaling approximately 11,000. Colonic polyps early in tumor progression pathway showed similar numbers events. These results indicate that,...
RNA interference (RNAi) mediated by small interfering RNAs (siRNAs) is a powerful new tool for analyzing gene knockdown phenotypes in living mammalian cells. To facilitate large-scale, high-throughput functional genomics studies using RNAi, we have developed microarray-based technology highly parallel analysis. Specifically, siRNAs transfection matrix were first arrayed on glass slides, overlaid with monolayer of adherent cells, incubated to allow reverse transfection, and assessed the...
AXL is activated by its ligand GAS6 and expressed in triple-negative breast cancer cells. In the current study, we report expression HER2-positive (HER2+) cancers where it correlates with poor patient survival. Using murine models of HER2+ cancer, Axl, but not Gas6, was found to be essential for metastasis. We determined that required intravasation, extravasation, growth at metastatic site. displaying epithelial-to-mesenchymal transition (EMT) signatures contributes sustain EMT. Interfering...
LBA2 Background: About 6% of newly diagnosed breast cancer patients present with Stage IV disease and an intact primary tumor (IPT). Locoregional treatment (LRT) for the IPT is hypothesized to improve survival based on retrospective analyses, but randomized trials have provided conflicting data. We now report results E2108, a Phase 3 trial that examined worth LRT following initial systemic therapy. Methods: were registered, treated optimal therapy (OST) patient characteristics; those who did...
The major obstacle in successfully treating triple-negative breast cancer (TNBC) is resistance to cytotoxic chemotherapy, the mainstay of treatment this disease. Previous preclinical models chemoresistance TNBC have suffered from a lack clinical relevance. Using single high dose chemotherapy treatment, we developed novel MDA-MB-436 cell-based model characterized by unique and complex morphologic phenotype, which consists polyploid giant cells giving rise neuron-like mononuclear daughter...
Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0, 1+, or 2+/in situ hybridization (ISH) negative]; approximately 60% BCs traditionally HER2-negative express low levels HER2. HER2-low (IHC 1+ IHC 2+/ISH-) status became clinically actionable with approval trastuzumab deruxtecan to treat unresectable/metastatic BC. Greater understanding patients disease is urgently needed.This...
In KATHERINE, adjuvant T-DM1 reduced risk of disease recurrence or death by 50% compared with trastuzumab in patients residual invasive breast cancer after neoadjuvant therapy (NAT) comprised HER2-targeted and chemotherapy. This analysis aimed to identify biomarkers response differences biomarker expression before NAT.Exploratory analyses investigated the relationship between disease-free survival (IDFS) HER2 protein expression/gene amplification, PIK3CA hotspot mutations, gene HER2, PD-L1,...
CXCR4 is a chemokine receptor implicated in the homing of cancer cells to target metastatic organs, which overexpress its ligand, stromal cell-derived factor (SDF)-1. To determine efficacy targeting on primary tumor growth and metastasis, we used peptide inhibitor CXCR4, CTCE-9908, that was administered clinically relevant approach using transgenic breast mouse model. We first performed dosing experiment CTCE-9908 PyMT model, testing 25, 50 100 mg/kg versus scrambled groups 8-16 mice. then...
We previously identified claudin-2 as a functional mediator of breast cancer liver metastasis. now confirm that levels are elevated in metastases, but not skin compared to their matched primary tumors patients with cancer. Moreover, is specifically expressed liver-metastatic cells populations derived from bone or lung metastases. The increased tropism exhibited by claudin-2-expressing requires claudin-2-mediated interactions between and hepatocytes. Furthermore, the reduction expression...
Nrf2 is the key transcription factor for cytoprotective gene programs. normally maintained at very low concentrations by proteasomal degradation, through its interaction with adapter protein Keap1 and Cul3 E3 ligase. Increased concentration resulting from loss of function mutations has been described in chemoresistant non-small cell lung cancer. Previous studies breast cancer showed levels some Nrf2-regulated detoxification genes, but mechanism not systematically examined. We found that half...
Introduction: Numerous diseases are caused by changes in post-translational modifications (PTMs). Therefore, the number of clinical proteomics studies that include analysis PTMs is increasing. Combining complementary information—for example protein abundance, PTM levels, with genome and transcriptome (proteogenomics)—holds great promise for discovering important drivers markers disease, as variations copy number, expression or mutations without spatial/functional/isoform information often...
High prion protein (PrP) levels are associated with breast, colon and gastric cancer resistance to treatment a poor prognosis for the patients. However, little is known about underlying molecular mechanism(s) regulating human PrP gene (PRNP) expression in cancers. Because endoplasmic reticulum (ER) stress solid tumors, we investigated possible regulation of PRNP by ER stress.Published microarray databases breast tissues carcinoma cell lines were analyzed mRNA marker immunoglobulin heavy...